Tango Therapeutics' drug vopimetostat combined with daraxonrasib has shown a promising early signal in treating pancreatic cancer, based on a small group of 12 previously treated patients. A larger Phase 3 trial is planned to test the drug as a first-line treatment, but details on its design and regulatory approval are still uncertain. Additional studies in lung cancer and CNS cancers will reveal if the drug can succeed beyond this initial result. While the company has enough funding for now, key trials and potential market launch are still years away, making the stock a cautious hold for investors.
VICI Properties is rated a Buy with a $30 price target, offering a potential 26% price increase plus an 8% dividend yield. The company maintains strong fundamentals including full occupancy, triple-net leases, and a long average lease term of nearly ...
QXO, Inc. is currently trading below its book value and at a market capitalization less than its recent acquisition of TopBuild, despite building a leading platform in building products distribution. The company reported a 70% year-over-year revenue ...
eBay CEO Jamie Iannone has sold company shares worth $2.3 million. This sale comes as eBay's stock has delivered a 12% return over the past year. The move may reflect personal financial planning or confidence in the company's current valuation. Inves...
PEPE, a meme coin, gained 15.4% over the past week, reaching $0.00000393 as of September 20, 2026. Despite rumors of whale buying, a fund launch, and a token buyback, no solid evidence supports these claims, which mostly appear as promotional content...
Bitcoin's 50-day moving average recently crossed above its 200-day average, a pattern known as a golden cross often seen as a buy signal. Historical data since 2014 shows that Bitcoin's price rose 90 days after eight out of eleven golden crosses, ave...
